**Component 2: Core Viral Hepatitis Prevention Activities**

**Reporting Agency**

|  |  |
| --- | --- |
| **Reporting jurisdiction** |  |
| **Contact name** (*person completing form*) |  |
| **Contact phone number** (*xxx-xxx-xxxx*) |  |
| **Contact email address** |  |
| **Additional contact name(s)** (*if applicable*) |  |
| **Additional contact phone number(s)** (*xxx-xxx-xxxx*) |  |
| **Additional contact email address(es)** |  |
| **Date of report submission** (*MM/DD/YYYY*) |  |
| **Reporting Period**(*Complete this form with information from Reporting Period selected*) |  *Select one* □ Year 1 (5/1/21-9/30/21) □ Year 2 (10/1/21-9/30/22) □ Year 3 (10/1/22-9/30/23) □ Year 4 (10/1/23-9/30/24) □ Year 5 (10/1/24-4/30/26)  |

**2.1—Support viral hepatitis elimination planning and surveillance,**

**and maximize access to testing, treatment, and prevention**

**Measures 2.1.1.a – 2.1.1.b**

* Establishment and maintenance of a viral hepatitis elimination technical advisory committee (or coalition) with membership to support jurisdictional viral hepatitis elimination planning
* Conduct at least two meetings per year of the viral hepatitis elimination technical advisory committee (or coalition)

|  |  |  |
| --- | --- | --- |
| **Have you established a viral hepatitis elimination technical advisory committee (or coalition) to support viral hepatitis elimination planning?** |  *Select one* □ Completed □ In progress | □ Not started |
| **Identify the stakeholder groups that are (or will be) represented on this committee (or coalition).**(*select all that apply*) | □ Public health□ Corrections□ Criminal justice, law enforcement□ Medicaid□ Injury prevention services□ Substance use and mental health services□ Healthcare providers □ HIV care providers□ Hospitals | □ Laboratories□ Community-based organizations□ Local harm reduction coalition members □ Non-profit/advocacy groups □ People with viral hepatitis lived experience□ Other, specify: >>□ N/A (committee not established)  |
| **During this reporting period, when did the committee (or coalition) meet?** (*MM/DD/YYYY*) | >> | >> |
| □ No meetings held during reporting period □ N/A (committee not established)  |
| **If the committee (or coalition) met during this reporting period, please submit** **a copy of meeting agenda(s) with the APR.**  |  *Select one* □ Submitted □ Not submitted□ N/A (committee not established)  |

**Measure 2.1.1.c**

* Development and maintenance of a viral hepatitis elimination plan with support from the technical advisory committee (or coalition)

|  |  |  |
| --- | --- | --- |
| **Have you developed a viral hepatitis elimination plan?** |  *Select one* □ Completed □ In progress | □ Not started |
| **Does it contain plans for elimination of hepatitis C and/or hepatitis B?**(*select all that apply*) | □ Hepatitis C□ Hepatitis B | □ N/A (plan not started)  |
| **If the viral hepatitis elimination plan is completed, please submit a copy with the APR.** |  *Select one* □ Submitted □ Not submitted□ N/A (plan not started)  |

**Measures 2.1.2.c, 2.1.4.a**

* The jurisdictional viral hepatitis elimination plan addresses recommendations for increasing HCV RNA reflex testing
* The jurisdictional viral hepatitis elimination plan addresses provider training in prescribing hepatitis C and hepatitis B treatment

|  |  |  |
| --- | --- | --- |
| **Does your viral hepatitis elimination plan address recommendations for increasing HCV RNA reflex testing?**  |  *Select one* □ Yes □ No | □ N/A (plan not started)  |
| **Does your viral hepatitis elimination plan address provider training in prescribing hepatitis C treatment?** |  *Select one* □ Yes □ No | □ N/A (plan not started)  |
| **Does your viral hepatitis elimination plan address provider training in prescribing hepatitis B treatment?** |  *Select one* □ Yes □ No |  □ N/A (plan not started)  |

**Measures 2.1.2.a – 2.1.2.b**

* CLIA-certified laboratories that conduct testing for at least 80% of all anti-HCV results identified in the jurisdiction
* The proportion conducting HCV RNA reflex testing was assessed; feedback with recommendations conducted

|  |  |
| --- | --- |
| **Have you worked with your surveillance and/or epidemiology teams to identify the total number of CLIA-certified laboratories in your jurisdiction that report hepatitis C antibody testing results?** |  *Select one* □ Yes □ No□ In progress |
| **Of the CLIA-certified laboratories you have identified that report hepatitis C antibody testing results, have you selected the subset that reports at least 80% of the hepatitis C antibody testing results in your jurisdiction?** |  *Select one* □ Yes □ No | □ In progress□ N/A (labs not identified) |
| **Of this subset, have you performed a needs assessment to identify key barriers and challenges to increasing HCV RNA reflex testing?** |  *Select one* □ Yes □ No | □ In progress□ N/A (labs not identified) |
| **What proportion of the subset is conducting HCV RNA reflex testing?** |  *Select one* %: | □ In progress□ N/A (labs not identified) |
| **Have you provided recommendations to increase HCV RNA reflex testing?** |  *Select one* □ Yes □ No |  □ In progress□ N/A (labs not assessed) |

**Measures 2.1.3.a – 2.1.3.b**

* The top 5 highest volume health systems in the jurisdiction identified
* The proportion of health systems promoting routine HCV and HBV testing assessed; feedback with recommendations was conducted

|  |  |
| --- | --- |
| **What are the top 5 highest volume health systems in your jurisdiction?** | 1.2.3.4.5.□ In progress□ Not started |
| **Have you assessed how many of these health systems are promoting routine HCV testing?** |  *Select one* □ Completed □ In progress  |  □ Not started□ N/A (health systems not assessed) |
| **If so, what percent of health systems are promoting routine HCV testing?** | %: | □ In progress □ N/A (health systems not assessed) |
| **Have you assessed how many of these health systems are promoting routine HBV testing?** |  *Select one* □ Completed □ In progress | □ Not started□ N/A (health systems not assessed) |
| **If so, what percent of health systems are promoting routine HBV testing?** | %: | □ In progress□ N/A (health systems not assessed) |
| **Have you provided feedback to the top 5 highest volume health systems with recommendations on promoting routine HCV and/ or HBV testing?** |  *Select one* □ Yes, to all 5 □ No, have not provided feedback to any of them | □ Yes, to some but not all□ N/A (health systems not assessed) |

|  |  |
| --- | --- |
| **Please use this space** **to provide information about challenges and successes experienced when implementing Strategy 2.1 activities. Include additional contextual information that would help us interpret your annual performance data.** |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **Was Section 2.2 funded?** |  *Select one* | □ No *NOTE: Stop here if not funded* | □ Yes |

-----------------------------------------------------------------------------------------------------------------------------------------------------

**2.2—Increase access to hepatitis C and/or hepatitis B testing and referral to care**

 **in high-impact settings**

**Measures 2.2.2.a – 2.2.2.b**

* Jurisdiction established relationship with partners in high-impact settings to identify high priority facilities for expansion of testing for HCV and/or HBV in high-impact settings, by setting type (syringe services programs, substance use disorder treatment programs, correctional facilities, emergency departments, hospital-based programs, sexually transmitted disease clinics, homeless services, health centers, other)
* Number of clients seen, by setting

|  |
| --- |
| During the reporting period, were component 2 activities conducted at one or more syringe services programs (SSPs)?□ Yes□ No  |
| During the reporting period, were component 2 activities conducted at one or more substance use disorder (SUD) treatment programs (non-hospital based)?□ Yes□ No  |
| During the reporting period, were component 2 activities conducted at one or more hospital-based substance use disorder (SUD) treatment programs? □ Yes□ No  |
| During the reporting period, were component 2 activities conducted at one or more hospital-based programs (excluding SUD treatment programs which are included separately above)?□ Yes□ No  |
| During the reporting period, were component 2 activities conducted at one or more health centers (non-hospital based)?□ Yes□ No  |
| During the reporting period, were component 2 activities conducted at one or more sexually transmitted infections (STI) clinics? □ Yes□ No  |
| During the reporting period, were component 2 activities conducted at one or more mobile clinics? □ Yes□ No  |
| During the reporting period, were component 2 activities conducted at one or more emergency departments? □ Yes□ No  |
| During the reporting period were component 2 activities conducted at one or more correctional facilities? □ Yes□ No  |
| During the reporting period were component 2 activities conducted at one or more homeless services? □ Yes□ No  |
| During the reporting period, were component 2 activities conducted at another type of setting?  □ Yes, specify: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_□ No Note: If more than one other type of setting, list the first other type here and describe the additional other type(s) individually in the following questions.  |
| During the reporting period, were component 2 activities conducted at a second other type of setting?  □ Yes, specify: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_□ No Note: If more than two other types of settings, list the second other type here and describe the additional other type(s) individually in the following questions.  |
| During the reporting period, were component 2 activities conducted at a third other type of setting? □ Yes, specify: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_□ No  |

|  |  |  |  |
| --- | --- | --- | --- |
| **Setting type** | **Was relationship established to expand HCV testing?** | **Was relationship established to expand HBV testing?** | **Number of clients seen at this setting during reporting period**  |
| **SSPs***questions will be skipped if not applicable* |  *Select one* □ Yes □ No □ In progress  |  *Select one* □ Yes □ No □ In progress  | >□ Unknown  |
| **SUD treatment programs, non-hospital based** *questions will be skipped if not applicable* |  *Select one* □ Yes □ No □ In progress  |  *Select one* □ Yes □ No □ In progress  | >□ Unknown  |
| **SUD treatment programs, hospital-based** *questions will be skipped if not applicable* |  *Select one* □ Yes □ No □ In progress  |  *Select one* □ Yes □ No □ In progress  | >□ Unknown  |
| **Hospital-based programs** (excluding SUD treatment programs which are included separately above)*questions will be skipped if not applicable* |  *Select one* □ Yes □ No □ In progress  |  *Select one* □ Yes □ No □ In progress  | >□ Unknown  |
| **Health centers (non-hospital based)***questions will be skipped if not applicable* |  *Select one* □ Yes □ No □ In progress  |  *Select one* □ Yes □ No □ In progress  | >□ Unknown  |
| **STI clinics***questions will be skipped if not applicable* |  *Select one* □ Yes □ No □ In progress  |  *Select one* □ Yes □ No □ In progress  | >□ Unknown  |
| **Mobile clinics***questions will be skipped if not applicable* |  *Select one* □ Yes □ No □ In progress  |  *Select one* □ Yes □ No □ In progress  | >□ Unknown  |
| **Emergency departments***questions will be skipped if not applicable* |  *Select one* □ Yes □ No □ In progress  |  *Select one* □ Yes □ No □ In progress  | >□ Unknown  |
| **Correctional facilities***questions will be skipped if not applicable* |  *Select one* □ Yes □ No □ In progress  |  *Select one* □ Yes □ No □ In progress  | >□ Unknown  |
| **Homeless services** *questions will be skipped if not applicable* |  *Select one* □ Yes □ No □ In progress  |  *Select one* □ Yes □ No □ In progress  | >□ Unknown  |
| **Other type of setting described above, first***questions will be skipped if not applicable* |  *Select one* □ Yes □ No□ In progress  |  *Select one* □ Yes □ No □ In progress  | >□ Unknown  |
| **Other type of setting described above, second***questions will be skipped if not applicable* |  *Select one* □ Yes □ No □ In progress  |  *Select one* □ Yes □ No □ In progress  | >□ Unknown  |
| **Other type of setting described above, third***questions will be skipped if not applicable* |  *Select one* □ Yes □ No □ In progress  |  *Select one* □ Yes □ No □ In progress  | >□ Unknown  |

**Measures 2.2.2.c – 2.2.2.f, 2.2.3.a**

* Number of clients screened for hepatitis C (anti-HCV), by setting
* Number of clients positive for anti-HCV, by setting
* Number of clients tested for HCV RNA, by setting
* Number of clients positive for HCV RNA, by setting
* Number of clients positive for HCV RNA linked to treatment, by setting

|  |  |
| --- | --- |
|  | **During this reporting period, number of:** |
| **Setting type** | **Clients screened for hepatitis C (anti-HCV)**  | **Clients positive for anti-HCV**  | **Clients tested for HCV RNA**  | **Clients positive for HCV RNA**  | **Clients positive for HCV RNA linked to hepatitis C treatment**  |
| **SSPs***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **SUD treatment programs, non-hospital based** *questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **SUD treatment programs, hospital based** *questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Hospital-based programs** (excluding SUD treatment programs which are included separately above)*questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Health centers (non -hospital based)***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **STI clinics***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Mobile clinics***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Emergency departments***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Correctional facilities***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Homeless services***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Other type of setting described above, first***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Other type of setting described above, second***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Other type of setting described above, third***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |

**Measures 2.2.2.g – 2.2.2.h, 2.2.3.b**

* Number of clients screened for hepatitis B, by setting
* Number of clients positive for HBsAg, by setting
* Number of clients positive for HBsAg linked to care, by setting

|  |  |
| --- | --- |
|  | **During this reporting period, number of:** |
| **Setting type** | **Clients screened for hepatitis B**  | **Clients positive for HBsAg**  | **Clients positive for HBsAg linked to hepatitis B care** |
| **SSPs***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **SUD treatment programs, non-hospital based** *questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **SUD treatment programs, hospital-based** *questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Hospital-based programs** (excluding SUD treatment programs which are included separately above)*questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Health centers (non- hospital based)***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **STI clinics***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Mobile clinics***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Emergency departments***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Correctional facilities***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Homeless services***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Other type of setting described above, first***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Other type of setting described above, second***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Other type of setting described above, third***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  |

|  |  |
| --- | --- |
| **Please use this space** **to provide information about challenges and successes experienced when implementing Strategy 2.2 activities. Include additional contextual information that would help us interpret your annual performance data.** |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **Was Section 2.3 funded?** |  *Select one* | □ No *NOTE: Stop here if not funded*  | □ Yes |

-----------------------------------------------------------------------------------------------------------------------------------------------------

**2.3—Improve access to services preventing viral hepatitis**

**and other bloodborne infections among people who inject drugs (PWID)**

**Measures 2.3.3.a – 2.3.3.d**

* Number of hepatitis A vaccination doses administered to clients in the high-impact settings, by setting
* Number of clients in the high-impact settings who completed hepatitis A vaccination series, by setting
* Number of hepatitis B vaccination doses administered to clients in the high-impact settings, by setting
* Number of clients in the high-impact settings who completed hepatitis B vaccination series, by setting

|  |  |
| --- | --- |
|  | **During this reporting period, number of:** |
| **Setting type** | **Hepatitis A vaccination doses administered**  | **Clients who completed hepatitis A vaccination series**  | **Hepatitis B vaccination doses administered**  | **Clients who completed hepatitis B vaccination series**  |
| **SSPs***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **SUD treatment programs, non-hospital based** *questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **SUD treatment programs, hospital-based** *questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Hospital-based programs** (excluding SUD treatment programs which are included separately above)*questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Health centers (non- hospital based)***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **STI clinics***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Mobile clinics***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Emergency departments***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Correctional facilities***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Homeless services***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Other type of setting described above, first***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Other type of setting described above, second***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |
| **Other type of setting described above, third***questions will be skipped if not applicable* | >□ Unknown  | >□ Unknown  | >□ Unknown  | >□ Unknown  |

**Measures 2.3.1.a – 2.3.1.d, 2.3.2.a**

* Number of syringe services programs (SSPs) in the jurisdiction
* Number of visits in the jurisdiction, by SSP
* Number of unduplicated SSP clients in the jurisdiction, by SSP
* Mean (median) syringe coverage rates, by SSP
* Number of clients linked to substance use disorder treatment by SSPs in the jurisdiction, by SSP

|  |  |  |
| --- | --- | --- |
|  | **During this reporting period, number of:** |  |
| **Syringe services programs (SSPs) in jurisdiction** | **Total client visits**  | **Unduplicated SSP clients**  | **Clients linked to substance use disorder treatment**  | **Mean syringe coverage rates during this reporting period** |
| **SSP 1****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 2****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 3****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 4****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 5****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 6****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 7****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 8****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 9****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 10****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 11****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 12****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 13****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 14****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 15****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 16****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 17****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 18****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 19****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 20****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 21****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 22****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 23****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 24****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 25****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 26****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 27****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 28****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 29****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 30****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 31****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 32****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 33****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 34****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 35****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 36****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 37****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 38****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 39****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 40****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 41****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 42****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 43****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 44****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 45****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 46****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 47****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 48****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 49****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |
| **SSP 50****Name:**> | >□ Unknown  | >□ Unknown  | >□ Unknown  | Mean= |

|  |  |
| --- | --- |
| **Please use this space** **to provide information about challenges and successes experienced when implementing Strategy 2.3 activities. Include additional contextual information that would help us interpret your annual performance data.** |  |